← Leaderboards
Maurice S Swanson
University Of California, San Diego
$17,857,475
Attributed
$23,552,924
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,482,034 · 12
By mechanism
R01$14,764,061 · 4
P50$6,299,283 · 4
P01$3,959,328 · 3
U54$1,459,362 · 1
Top collaborators
- Eugene Wei-Ming Yeo8 shared
- Laura Pw Ranum6 shared
- John A Berglund5 shared
- Robert C Spitale5 shared
- Eric T Wang5 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Cornelis Murre$34,901,163
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsMouse ModelAffectMicrosatellite RepeatsMyotonic DystrophyGenesAdultMediatingEventRna SplicingMolecularIn VivoMuscular DystrophiesBaseLinkDefectTissuesMutantUntranslated RegionsGenetic TranscriptionPathogenesisRna ProcessingNeuromuscular DiseasesAlternative Splicing
Grant awards (61)
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center$1,456,513
P50 · FY2025 · NS · contact PI
Therapeutic strategies for microsatellite expansion diseases using RNA targeting$627,181
R01 · FY2025 · NS
DM2 pathomechansims and therapeutic development$363,426
P50 · FY2025 · NS · contact PI
Administrative Core$59,301
P50 · FY2025 · NS · contact PI
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center$1,472,597
P50 · FY2024 · NS · contact PI
Therapeutic strategies for microsatellite expansion diseases using RNA targeting$616,080
R01 · FY2024 · NS
DM2 pathomechansims and therapeutic development$364,709
P50 · FY2024 · NS · contact PI
Administrative Core$58,907
P50 · FY2024 · NS · contact PI
Therapeutic strategies for microsatellite expansion diseases using RNA targeting$657,364
R01 · FY2023 · NS
Preclinical models, biomarkers, and therapy for myotonic dystrophy type 1$493,747
P50 · FY2022 · NS · contact PI
Therapeutic strategies for microsatellite expansion diseases using RNA-targeting CRISPR/Cas$590,464
R01 · FY2021 · NS
Preclinical models, biomarkers, and therapy for myotonic dystrophy type 1$492,139
P50 · FY2021 · NS · contact PI
Molecular Characterization of ALS/FTD in a novel C9orf72 BAC mouse model.$695,423
R01 · FY2020 · NS
Therapeutic strategies for microsatellite expansion diseases using RNA-targeting CRISPR/Cas$600,524
R01 · FY2020 · NS
Preclinical models, biomarkers, and therapy for myotonic dystrophy type 1$510,858
P50 · FY2020 · NS · contact PI
Determining the factors that control dose-dependent splicing regulation by a master regulator$414,445
R01 · FY2020 · GM
Molecular Characterization of ALS/FTD in a novel C9orf72 BAC mouse model.$705,907
R01 · FY2019 · NS
Therapeutic strategies for microsatellite expansion diseases using RNA-targeting CRISPR/Cas$611,348
R01 · FY2019 · NS
Preclinical models, biomarkers, and therapy for myotonic dystrophy type 1$501,929
P50 · FY2019 · NS · contact PI
Determining the factors that control dose-dependent splicing regulation by a master regulator$446,800
R01 · FY2019 · GM
Molecular Characterization of ALS/FTD in a novel C9orf72 BAC mouse model.$741,646
R01 · FY2018 · NS
Therapeutic strategies for microsatellite expansion diseases using RNA-targeting CRISPR/Cas$622,054
R01 · FY2018 · NS
Preclinical models, biomarkers, and therapy for myotonic dystrophy type 1$525,157
P50 · FY2018 · NS · contact PI
Determining the factors that control dose-dependent splicing regulation by a master regulator$407,973
R01 · FY2018 · GM
Determining the factors that control dose-dependent splicing regulation by a master regulator$32,354
R01 · FY2018 · GM
Molecular Characterization of ALS/FTD in a novel C9orf72 BAC mouse model.$839,776
R01 · FY2017 · NS
Therapeutic strategies for microsatellite expansion diseases using RNA-targeting CRISPR/Cas$640,125
R01 · FY2017 · NS
MECHANISMS OF RNA-MEDIATED CNS PATHOGENESIS IN MYOTONIC DYSTOPHY$425,769
P01 · FY2017 · NS · contact PI
Determining the factors that control dose-dependent splicing regulation by a master regulator$421,098
R01 · FY2017 · GM
Molecular Characterization of ALS/FTD in a novel C9orf72 BAC mouse model.$773,641
R01 · FY2016 · NS
MECHANISMS OF RNA-MEDIATED CNS PATHOGENESIS IN MYOTONIC DYSTOPHY$344,902
P01 · FY2016 · NS · contact PI
Molecular Characterization of ALS/FTD in a novel C9orf72 BAC mouse model.$85,360
R01 · FY2016 · NS
MECHANISMS OF RNA-MEDIATED CNS PATHOGENESIS IN MYOTONIC DYSTOPHY$352,496
P01 · FY2015 · NS · contact PI
MECHANISMS OF RNA-MEDIATED CNS PATHOGENESIS IN MYOTONIC DYSTOPHY$355,959
P01 · FY2014 · NS · contact PI
RNA Dominance in Human Disease$304,528
R01 · FY2014 · AR · contact PI
MECHANISMS OF RNA-MEDIATED CNS PATHOGENESIS IN MYOTONIC DYSTOPHY$366,143
P01 · FY2013 · NS · contact PI
RNA Dominance in Human Disease$295,912
R01 · FY2013 · AR · contact PI
RNA Dominance in Human Disease$312,132
R01 · FY2012 · AR · contact PI
Mechanisms of RNA-mediated CNS Pathogenesis in Myotonic Dystrophy$278,268
P01 · FY2012 · NS · contact PI
Mechanisms of RNA-mediated CMS Pathogenesis in Myotonic Dystrophy$353,933
P01 · FY2011 · NS · contact PI
RNA Dominance in Human Disease$312,694
R01 · FY2011 · AR · contact PI
Mechanisms of RNA-mediated CMS Pathogenesis in Myotonic Dystrophy$364,602
P01 · FY2010 · NS · contact PI
Mechanisms of RNA-mediated CMS Pathogenesis in Myotonic Dystrophy$360,541
P01 · FY2010 · NS · contact PI
RNA Dominance in Human Disease$326,232
R01 · FY2010 · AR · contact PI
Mechanisms of RNA-mediated CMS Pathogenesis in Myotonic Dystrophy$378,475
P01 · FY2009 · NS · contact PI
RNA Dominance in Human Disease$297,443
R01 · FY2009 · AR · contact PI
Mechanisms of RNA-mediated CMS Pathogenesis in Myotonic Dystrophy$378,240
P01 · FY2008 · NS · contact PI
RNA Dominance in Human Disease$297,443
R01 · FY2008 · AR · contact PI
RNA Dominance in Human Disease$303,513
R01 · FY2007 · AR · contact PI
Mouse Muscleblind Model for Myotonic Dystrophy$283,972
U54 · FY2007 · NS · contact PI
RNA Dominance in Human Disease$312,578
R01 · FY2006 · AR · contact PI
MOUSE MUSCLEBLIND MODEL FOR MYOTONIC DYSTROPHY$290,380
U54 · FY2006 · NS · contact PI
RNA Dominance in Human Disease$320,100
R01 · FY2005 · AR
MOUSE MUSCLEBLIND MODEL FOR MYOTONIC DYSTROPHY$294,330
U54 · FY2005 · NS
MOUSE MUSCLEBLIND MODEL FOR MYOTONIC DYSTROPHY$292,429
U54 · FY2004 · NS
RNA DOMINANCE IN HUMAN DISEASE$231,392
R01 · FY2004 · AR
MOUSE MUSCLEBLIND MODEL FOR MYOTONIC DYSTROPHY$298,251
U54 · FY2003 · NS
RNA DOMINANCE IN HUMAN DISEASE$231,670
R01 · FY2003 · AR
RNA DOMINANCE IN HUMAN DISEASE$231,923
R01 · FY2002 · AR
RNA DOMINANCE IN HUMAN DISEASE$232,152
R01 · FY2001 · AR
RNA DOMINANCE IN HUMAN DISEASE$224,786
R01 · FY2000 · AR